GLOW BLEND

TB-500 + BPC-157 + GHK-Cu—EVIDENCE MAP

Benefits, research claims, evidence boundaries, and safety context—in one page.

3-PEPTIDE BLEND

NO EXACT-BLEND TRIAL

WHAT THE EVIDENCE IS STUDYING

The GLOW blend combines TB-500, BPC-157, and GHK-Cu around skin, repair, and recovery themes. The exact combination has not been clinically validated.

RESEARCH PROFILE

- **Components**
  TB-500 / BPC-157 / GHK-Cu
- **Claimed theme**
  Skin + repair
- **Clinical status**
  Not FDA-approved

EVIDENCE REALITY CHECK

GHK-Cu has route-specific cosmetic research; BPC-157 is supported mainly by animal work; and TB-500 claims often borrow from full-length Tβ4. Combining them does not convert these gaps into evidence.

BEST WAY TO DESCRIBE IT

A complex research blend with no proven human synergy.

SCAN FOR THE LIVE GUIDE

Opens the current printable PDF at rippedtidebiolabs.com.

Permanent Education Center resource link.

1 GHK-Cu CONTEXT

Topical and laboratory studies explore matrix remodeling, collagen signaling, and wound biology. Injectable outcomes are not established.

2 BPC-157 CONTEXT

Animal models report repair-related signals across several tissues. Adequate human efficacy trials are absent.

3 TB-500 CONTEXT

Evidence for thymosin beta-4 cannot be assumed to prove the activity of a marketed TB-500 fragment.

4 FINISHED-BLEND GAP

No adequate human trial establishes identity, dosing, interaction, safety, or cosmetic or healing efficacy for this three-peptide mixture.

IMPORTANT SAFETY + REGULATORY NOTE

GLOW is not FDA-approved. Three active peptides increase uncertainty about immune reactions, impurities, angiogenesis-related effects, systemic copper exposure, and injectable sterility. Aesthetic branding does not establish safety, pharmaceutical identity, or clinical benefit. Educational only—not a recommendation to use.

Sources: GHK-Cu: Pickart et al., Biomed Res Int. 2015; BPC-157 review: Thanasas et al. 2025; Tβ4 wound research: Malinda et al. 1999; FDA compounding safety resources.